Back to the Future: In-Person Partnering Conferences are Back with a Vengeance!

13 Oct

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

If the pandemic taught us anything, it is that there is more than one way to skin a cat. Making connections and doing business while being hundreds or thousands of miles apart from our counterparts seemed like a ridiculous proposition only a few years ago, but alas! Nobody thinks that way today.

In fact, the RESI conference successfully created a digital platform for exactly that: making connections and doing business. Early-stage companies, investors, strategics and service providers discovered how to make the best of the situation and be very productive. The usefulness of remote, virtual meetings is evident today and will likely be around for the foreseeable future. But we saw last month at RESI Boston that there is a real desire to return to face-to-face gatherings.

_DSC1104

While virtual meetings will continue to be useful, the return to in-person partnering conferences like RESI Boston and the upcoming RESI San Francisco, January10-12 have important advantages:

  • Ad-hoc meetings throughout the day
  • Networking receptions
  • The undeniable power of a handshake (or elbow bump!)

To that end, any company in the early-stage life sciences arena must have JPM week in January in San Francisco on their radar. It’s the week that thousands of relevant investors, strategic partners and new technology startups converge on the City by the Bay to look for opportunities to connect and do business. Apart from scheduling planned meetings throughout the week, every evening is full of networking events to make more connections. It can be the most productive week of the year for many companies!

RESI San Francisco,, January 10-12, 2023 is a key part of JPM week. For early-stage players, it is, without a doubt, the best venue to identify and meet 500+ global investors and strategic partners. The RESI Partnering Platform allows you to schedule multiple meetings with the right counterparts on January 10. For the following two days, you can schedule both virtual and in-person meetings anywhere in the city using the RESI Partnering Platform.

As a lead-up to JPM week, LSN is offering a Digital RESI, November 15-16 partnering event. You can meet virtually with 200+ investors and strategics to get the most out of the final quarter of 2022 and be ready for new and follow-up meetings in January. We are offering a super discount bundle package for RESI November & RESI JPM San Francisco.

Bundle Package Earlybird Offer – Digital RESI November + RESI JPM San Francisco

RESI-November-2022-2-border

RESI-SF-2023-Banner

Hot Investor Mandate: New Venture Capital Fund Seeks Early-Stage Therapeutics, Medical Device, and Diagnostics Investment Opportunities in USA and Canada

13 Oct

A venture capital fund in the process of raising USD 150 million will be used to invest in around ten to twelve early-stage startups. The fund will primarily look to participate in Series A fundraising but is open to earlier rounds as well. The firm will only participate in equity investments with an initial check size between USD 3 million and USD 7 million. The fund will primarily invest in companies that are based in the United States but is open to considering opportunities in Canada as well.

The firm is interested in investing in companies within the therapeutics, diagnostics, and medical technology sectors. The fund is modality agnostic and open to all companies within these sectors but will not consider investments in digital health. The firm will primarily seek to invest in therapeutics in the pre-clinical and Phase I stages of development as well as devices and diagnostics that are in development and clinical. The fund will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm prefers to work with experienced management teams that are made up of passionate and driven people developing great science. The fund is an active investor that will require a board seat and may act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Generics Company Invests Globally in Digital Health Companies in the Fields of Chronic Disease, Mental Health, and More

13 Oct

A corporate venture capital arm of a global generic manufacturer headquartered in Western Europe can invest up to $5m in a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Invests in Tech-Enabled Medtech and Digital Health Companies, With Preference to Those in Clinical Stage

13 Oct

A USA-based venture capital firm had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Fund Invests in the Earliest Stage Companies, Focusing on Pre-Seed Opportunities in Platform Technologies Including Therapeutics, Digital Health, and More

13 Oct

A thesis-driven earliest stage firm looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund of USD 67 million. The firm primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America.

The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

NIA Startup Challenge Finalists Shine in New Course

6 Oct

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Last month, Life Science Nation (LSN) was honored to collaborate with The National Institute on Aging to provide our newest entrepreneurial course to the 20 finalists of the Healthy Aging Start-Up Challenge. The course consists of two pre-course digital sessions and two in-person days leading up to RESI Boston, which helped prepare the participants for global partnering initiatives.

The program started with two 2-hour pre-course virtual sessions, aiming to introduce the timeline, required tools, and materials of a fundraising campaign, as well as the fundamental knowledge of different types of investors and strategies for successful partnering.

NIA01

The 2-Day Entrepreneurial Immersion Course, hosted at the Boston Marriott Copley Place, was delivered by LSN faculty and invited industry experts. The cohort received step-by-step instructions on managing global investor target lists and fundraising campaigns, and had interactive exercises on practicing tagline and elevator pitches with their mentors face-to-face, which motivated the innovators to polish their pitch with prompt guidance.

NIA02 NIA03
NIA04 NIA05

A Shark Tank exercise concluded the course with each finalist delivering their pitch presentations to an investor panel of five, each with rich experience in the early-stage life science arena. Both NIA team and the entire faculty was highly impressed by how much the messaging had improved since the first day. Benefitting from the real-time feedback, many finalists considered the Shark Tank a vital rehearsal exercise before heading to RESI for investor meetings.

NIA06

NIA07

Feedback from the cohort of the NIA startup challenge:

“This was an amazing course. We had the opportunity to revise our tagline and elevator pitch with the feedback of our colleagues. We learned about various important topics related to launching a company. The mentors provided the support and guidance that we needed to keep improving and bring our innovation to life.” 

“The RESI Conference was great for me. I casually met very impressive people in the digital health field, in the legal field, and in the venture capital field. I presented in the digital health group. The partnering platform was good to use to lead folks towards my startup as a bridge to a greeting. The platform itself also was structural in my approach to meet potential investors as a warm introduction. The platform was mentally structural in helping arrange my future fundraise.” 

Transitioning from the world of academia to business is never easy, but the process can be efficient with directions from experts on what to expect and how to proceed. LSN continues building bridges between scientists and CEOs by offering more Entrepreneurial Courses to incubators, accelerators, and non-profit organizations worldwide. Contact us to learn more!

NIA08

RESI-November-2022-2-border

RESI Hybrid Bundle

6 Oct

By Rory McCann, Director of Marketing & Conference Producer, LSN

Given the very recent success of Life Science Nation (LSN)’s first in-person event in 2+ years, RESI Boston, the demand for early-stage life science partnering opportunities is higher than ever. LSN’s pivot to digital events proved that there is a need for virtual partnering to accommodate the high volume of deals in the sector with limited logistics. However, there is no replacement for a face-to-face meeting or connections over coffee. Therefore, LSN continues to develop both hybrid and virtual events, and is offering a special deal on both!

RESI San Francisco, January 10-12, 2023 is our return to the West Coast for a 3-day hybrid experience. In-person RESI kicks us off the first day, featuring expert panels, educational workshops, and the Innovator’s Pitch Challenge. This is followed by an additional two days of virtual partnering to accommodate the hustle and bustle of healthcare’s biggest partnering week of the year. Fundraising doesn’t start and stop with partnering events, which is why we are bundling Digital RESI, November 15-16 and RESI San Francisco registrations to enable continuous connections through the end of the year and the beginning of next.

Startups and Service Providers can save $1,000 on their bundle when they register by October 21. We hope you’ll join us and take advantage of the opportunity to maximize your fundraising efforts and meet with investors and strategic partners who are a fit for your product and stage of development. Bundle and save by October 21 for both Digital RESI November and RESI San Francisco!

RESI-November-2022-2-border

RESI-SF-2023-Banner